Nolen Appointed to Taxotere Plaintiff's Steering Committee

Fleming, Nolen & Jez lawyer Rand Nolen has been appointed to the Plaintiff’s Steering Committee in federal Taxotere litigation. Judge Kurt D. Engelhardt appointed Nolen and thirteen other nationally recognized lawyers to head up the litigation for injured plaintiffs.

“This is an exciting opportunity to lead the charge for women who have unfortunately had to endure the horror of cancer, only to discover that the medicine used to treat them has left them balding or in some cases completely without hair,” Nolen said after learning of his appointment to the leadership team.

In October, the U.S. Judicial Panel on Multidistrict Litigation ordered federally-filed Taxotere lawsuits consolidated in Louisiana district court. Since that time, cases throughout the United States involving the breast cancer treatment drug have commenced being transferred for consolidated proceedings.

The lawsuits against pharmaceutical company Sonafi SA allege that the company promoted Taxotere as being superior to its competitors’ chemotherapy drugs despite knowing that Taxotere carried a permanent hair loss risk that the others did not. According to the complaints, the promotion of Taxotere was highly successful with sales jumping from approximately $424 million in 2000 to approximately $1.4 billion in just 4 years.

Temporary hair loss can be a common and well-known side effect of chemotherapy. However, permanent hair loss or permanent alopecia is neither a common nor well-known side effect. Yet, hundreds or even thousands of women have developed permanent hair loss after being treated with Taxotere.

Related Posts:

Categories: Defective Drugs, Taxotere